(UroToday.com) The long-term efficacy and tolerability of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg Q3W × 4 doses followed by nivolumab 3 mg/kg Q2W for previously untreated advanced renal cell carcinoma (RCC) demonstrated in the registrational CheckMate 214 clinical trial1 was based on patients with a predominantly clear cell component. Current data on the clinical activity of nivolumab plus ipilimumab in non-clear cell RCC are limited and largely based on retrospective analyses and thus prospective studies are needed. CheckMate 920 (NCT02982954) is a US community-based, multi-arm, phase IIIb/IV clinical trial of nivolumab plus ipilimumab treatment in patients with previously untreated advanced RCC and clinical features mostly excluded from phase III trials (ie non-clear cell RCC, brain metastases, and poor performance status). At the GU ASCO 2021 annual meeting, Dr. Scott Tykodi and colleagues presented the safety and efficacy results for cohort 2 patients with non-clear cell RCC from CheckMate 920, a patient population with a poor prognosis and without definitive effective treatment.